Introduction
============

COPD is a life-threatening lung disease and is the fourth leading cause of death worldwide.[@b1-copd-11-2741] It is known that COPD has a great impact on a patient's life. Symptoms frequently reported by patients with COPD are dyspnea, wheezing, cough, and sputum production.[@b2-copd-11-2741]

For many years, the concept chronic bronchitis (CB) has been investigated in patients with COPD. The proportion of patients reporting CB, defined as chronic productive cough, varies from 24.5%[@b3-copd-11-2741] to 82%.[@b4-copd-11-2741] Research concerning CB focused mainly on disease progression,[@b3-copd-11-2741],[@b4-copd-11-2741] with reduced forced expiratory volume in 1 second (FEV~1~) and Tiffeneau index (ratio FEV~1~/forced vital capacity \[FVC\]) as end points, in comparison to nonpersistent sputum producers.[@b3-copd-11-2741],[@b4-copd-11-2741] Furthermore, different studies observed an increase in the number of exacerbations[@b3-copd-11-2741],[@b4-copd-11-2741] and hospitalizations,[@b4-copd-11-2741] as well as a higher mortality risk.[@b5-copd-11-2741] Subsequently, a reduced quality of life[@b6-copd-11-2741] and functional exercise capacity[@b3-copd-11-2741] have been previously reported.

Not all patients have symptoms of productive cough; some have only increased mucus production. Mucus hypersecretion (MH) is characterized by an increase in mucin-producing cells, leading to increased mucus secretion.[@b7-copd-11-2741] CB and MH can simultaneously exist, although Caramori et al[@b8-copd-11-2741] concluded that there was no link between symptoms of CB and mucus production. MH was related to FEV~1~ decline, hospitalization,[@b9-copd-11-2741] and exacerbation frequency.[@b10-copd-11-2741] Contrary results have been published concerning the association with mortality.[@b11-copd-11-2741]

Although data are available on CB and MH, little is known about the association of spontaneous sputum production at any moment and health status and other clinical outcomes in patients with COPD. Especially, the potential impact of sputum microbiology on these outcomes might be clinically relevant because a substantial proportion of stable patients with COPD are colonized with bacteria,[@b12-copd-11-2741] which is associated with increased daily symptoms[@b13-copd-11-2741] and exacerbation frequency.[@b14-copd-11-2741] Banerjee et al[@b15-copd-11-2741] reported a worse health status in stable COPD patients with a positive sputum culture compared to patients without bacterial pathogens in sputum. These last data were limited because the focus of the research was different, and substantial information is lacking (eg, no mean values, only *P*-values).

Therefore, the aim of the present study was to increase understanding of the impact of spontaneous sputum production on health status and clinical characteristics in patients with COPD, after stratification between those with and without positive sputum cultures.

Materials and methods
=====================

The current analyses were based on data collected as part of the COPD, health status, and comorbidities (Chance) study, an observational monocenter study.[@b16-copd-11-2741] The rationale and design of the study have been previously published.[@b16-copd-11-2741] Chance was approved on April 23, 2012 by the local ethics committee of the Maastricht University Medical Centre+, the Netherlands (MEC 11-3-070). The authors confirm that all ongoing and related trials are registered (NTR3416, registered at [www.trialregister.nl](http://www.trialregister.nl)). All patients gave written informed consent.

Study population
----------------

Stable patients with COPD referred for pulmonary rehabilitation (PR) to CIRO, a Center of Expertise for Chronic Organ Failure, were consecutively recruited between April 23, 2012 and September 24, 2014 and were included in the current analyses. Patients were classified as COPD based on post-bronchodilator FEV~1~/FVC \<0.7 according to the Global Initiative for Obstructive Lung Disease (GOLD).[@b1-copd-11-2741] COPD Assessment Test (CAT) total score was used as symptom measure for the combined COPD assessment.[@b1-copd-11-2741] When CAT score was missing, the modified Medical Research Council score was used instead.[@b1-copd-11-2741] Stable was defined as not having a registered exacerbation in the past 4 weeks. Patients with a history of other respiratory diseases, having undergone lung surgery, or with a malignancy within the last 5 years were excluded from the study.[@b17-copd-11-2741]

Study procedures
----------------

Patients were measured during an inpatient pre-rehabilitation assessment. Clinical characteristics were assessed as described before.[@b16-copd-11-2741] Exacerbation history and hospital and ICU admission were based on the medical report and patient recall. CB was defined as the presence of chronic cough and sputum production for at least 3 months a year, for two consecutive years.[@b1-copd-11-2741] Disease-specific health status was assessed by CAT,[@b18-copd-11-2741] the Clinical COPD Questionnaire (CCQ),[@b19-copd-11-2741] and the COPD-specific version of the St George's Respiratory Questionnaire (SGRQ-C).[@b20-copd-11-2741] CAT items on cough and phlegm were stratified based on the number of points reported by patients, with a cutoff of ≥3 points. Besides, the following minimum clinically important differences (MCID) were taken into account: ≥2 points CAT,[@b21-copd-11-2741] ≥0.4 points CCQ,[@b22-copd-11-2741] and ≥4 points SGRQ-C.[@b23-copd-11-2741] Symptoms of anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS).[@b24-copd-11-2741] Exercise capacity was assessed by the 6-minute walking distance (6MWD).[@b25-copd-11-2741] Moreover, laboratory data including inflammatory parameters and blood gas analysis were collected. All patients were asked to produce spontaneous sputum if possible. Sputum samples were cultured to obtain the microbial etiology. Patients were categorized into two subgroups: nonsputum producers (NP) and sputum producers (SP), with the last group stratified by culture result; SP with a negative culture (SC−) and SP with a positive culture (SC+).

Statistical analysis
--------------------

SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) was used for data analyses. Variables were tested for normality using the skewness and kurtosis statistics. Continuous data are presented as mean ± standard deviation or median (interquartile range), while categorical data are presented as counts and percentages. Subgroups were compared using one-way analysis of variance and post hoc Bonferroni test, Kruskal--Wallis test for k- and 2-independent samples, or chi-square test, as appropriate. A *P*-value \<0.05 was considered to be statistically significant.

Results
=======

In total, 518 clinically stable patients with COPD were recruited (mean age 64.1±9.1 years, 55.6% males, FEV~1~ 48.6%±20.0% pred; [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=117079.pdf)). Of these, 164 patients (31.7%) produced a spontaneous sputum sample during their PR assessment. When comparing NP with SP, SP had a higher number of males, were more often classified as COPD GOLD D, were more frequent exacerbators, had more hospitalizations, and the prevalence of CB was higher ([Table S1](https://www.dovepress.com/get_supplementary_file.php?f=117079.pdf)).

To see whether these differences between NP and SP could be explained by the sputum microbiology, [Table 1](#t1-copd-11-2741){ref-type="table"} gives an overview of the baseline characteristics of NP, SC+, and SC−. A positive sputum culture was obtained in 53 patients (32.3%) with a sample. SC+ were more often males compared with NP, and more frequently classified as COPD GOLD D. No discrimination based on culture result could be made for the number of exacerbations in the year prior to assessment and symptoms of CB, although there was a trend toward increased exacerbations (*P*=0.058) and symptoms of CB (*P*=0.061) in SC+ vs SC−. In patients with CB (n=167), 78 patients produced a spontaneous sputum sample (46.7%). No differences were observed in medication use between the defined subgroups ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=117079.pdf)).

Health status, depression, and anxiety
--------------------------------------

Health status using CAT total, cough and phlegm score, SGRQ-C total and symptom score, and CCQ-total score were worse in SP compared to NP ([Table S3](https://www.dovepress.com/get_supplementary_file.php?f=117079.pdf)), although the differences did not exceed the MCID for all total scores. The sputum microbiology was discriminating in CAT total ([Figure 1](#f1-copd-11-2741){ref-type="fig"}) and CCQ total ([Figure 1](#f1-copd-11-2741){ref-type="fig"}), with worse scores in SC+ compared with NP (23.9±6.1 vs 21.1±6.7, *P*=0.012; 3.1±1.0 vs 2.5±1.0, *P*=0.002; respectively). CAT cough and phlegm ([Figure 1](#f1-copd-11-2741){ref-type="fig"}) and SGRQ-C symptom score ([Figure 1](#f1-copd-11-2741){ref-type="fig"}) were increased in both SC+ and SC− compared with NP ([Table S4](https://www.dovepress.com/get_supplementary_file.php?f=117079.pdf)). SGRQ-C total score was not significantly different anymore when taking the sputum microbiology into account, although the MCID was reached comparing SC+ with NP (65.4±16.1 vs 60.0±17.0). Additionally, the MCID was reached for SGRQ-C impact comparing SC+ with NP (53.8±21.6 vs 48.4±20.7). A significant difference between SC+ and SC− was observed in CAT phlegm (3.1±1.1 vs 2.5±1.3, *P*=0.020) and an MCID in SGRQ-C symptom score (71.3±17.5 vs 66.0±18.2; [Table S4](https://www.dovepress.com/get_supplementary_file.php?f=117079.pdf)).

When stratifying CAT cough and phlegm items based on reported scores, a significantly larger proportion of SC+ and SC− reported scores ≥3 points compared with NP (38 \[74.5%\] vs 66 \[60.6%\] vs 162 \[47%\], *P*\<0.001; 38 \[74.5%\] vs 55 \[50.5%\] vs 134 \[38.8%\], *P*\<0.001; respectively).

Symptoms of depression by the HADS score ([Figure 1F](#f1-copd-11-2741){ref-type="fig"}) were more often observed in SC+ compared to NP (8.7±4.1 vs 7.2±4.3). When comparing groups based on the proportion of patients with an elevated score on health status or symptoms of anxiety and depression, no significant differences appeared ([Table S5](https://www.dovepress.com/get_supplementary_file.php?f=117079.pdf)).

Exercise capacity
-----------------

Exercise capacity, assessed using the 6MWD, did not differ between NP and SP (424.8±124.7 vs 422.3±124.1 m).

Inflammatory parameters and microbial etiology
----------------------------------------------

[Table 2](#t2-copd-11-2741){ref-type="table"} shows the inflammatory parameters, with no differences between NP and SP.

The frequency of the detected pathogens in the 53 patients with positive culture is presented in [Figure 2](#f2-copd-11-2741){ref-type="fig"}. *Haemophilus influenzae* was most frequently present (39.6%), followed by *Pseudomonas aeruginosa* (28.3%). Coinfections existed, as a total of eleven patients were positive for more than one pathogen.

Discussion
==========

The results of this study can be summarized as follows. Almost one-third of patients with COPD referred for PR were identified as being spontaneous sputum producers. Also, it was shown that patients with COPD who had a sputum sample with a positive culture had worse health status compared with NP. Moreover, these patients had a higher exacerbation frequency and more symptoms of CB. Thus, not the presence of spontaneous sputum production per se, but its microbiological characterization influences outcomes in these patients.

Frequency of spontaneous sputum production
------------------------------------------

Spontaneous sputum production at any moment was very common in the present study and was associated with increased CAT cough and phlegm scores and an increased frequency of CB. Previously, Putcha et al[@b5-copd-11-2741] observed that sputum alone, or in combination with cough, was reported by 43.1% of 5,887 patients with mild-to-moderate airflow obstruction in the Lung Health Study. A study focusing on symptom variability in 2,441 stable patients with severe COPD showed that sputum was the second most experienced symptom after breathlessness (63.6%).[@b2-copd-11-2741] Although around 30% of these patients reported a low frequency of sputum production in the past 7 days, \~20% reported moderate and \~10% severe or extreme production.[@b2-copd-11-2741] Taking these proportions into consideration, it must be concluded that sputum production is common in patients with COPD, highlighting the potential importance of this specific clinical profile.

Impact on outcomes
------------------

Health status is an important outcome in the management of COPD. Until now, studies showed that health status is worse in patients with symptoms of CB,[@b3-copd-11-2741],[@b6-copd-11-2741],[@b26-copd-11-2741] mostly based on SGRQ scores. The results support the finding that health status is worse in patients with sputum production, especially in those with a positive culture (CAT total and CCQ total), even when compared with patients with a negative culture (CAT phlegm and SGRQ-C symptom). So, it seems that sputum production influences the symptom domains, while the sputum microbiology influences health status in general. Within the subgroup of patients with CB, however, health status was not affected by sputum culture. This suggests that sputum microbiology may be clinically relevant, especially in COPD patients with incidental sputum production. Although SGRQ-C total score and the domain score impact were not statistically significantly different, the difference observed between patients with a positive sputum culture and those without sputum production exceeded the MCID.

Limited data are available concerning symptoms of anxiety and depression in relation to CB. Corhay et al[@b4-copd-11-2741] reported no difference in symptoms of depression comparing patients with and without CB. The current data showed no difference in anxiety scores, although a significantly higher depression score was observed in patients with a positive sputum culture. Whether treatment of CB can lead to a decrease in symptoms of depression is not known and need further research.

It can be argued whether sputum production affects exercise capacity, as no differences were observed in 6MWD, as well as in SGRQ-C activity. Kim et al[@b6-copd-11-2741] made similar observations in patients with CB. However, this is not supported by others, who observed a reduced 6MWD in patients with CB compared to patients without.[@b3-copd-11-2741],[@b26-copd-11-2741] In the population of this study, sputum production did not seem to affect exercise capacity at baseline, but it would be interesting to see whether sputum production affects long-term exercise capacity. Moreover, the effect of sputum production on physical activities in daily life would be clinically relevant to investigate.

Remarkably, no differences in inflammatory parameters of blood samples were observed between NP and patients with sputum production. Although all patients were in a clinically stable state at time of assessment, a positive sputum culture may indicate microbial colonization. Indeed, worse outcomes were previously described in colonized patients with COPD concerning exacerbation frequency and daily symptoms, when compared with noncolonized patients.[@b13-copd-11-2741],[@b14-copd-11-2741] Although the current study design does not allow to firmly establish colonization, it suggests that sputum microbiology, instead of sputum production per se, affects health status.

The observed difference in frequency of sputum production between sexes might be explained by sex-related differences in reporting respiratory symptoms. Lamprecht et al[@b27-copd-11-2741] observed that females more often reported respiratory symptoms such as dyspnea and cough compared to males. In contrast, males more often reported sputum production.[@b27-copd-11-2741] This in accordance with other studies that observed the same differences between the sexes regarding the presence of CB.[@b3-copd-11-2741],[@b6-copd-11-2741]

Microbiological characterization
--------------------------------

The sputum microbiology confirms that *H. influenzae* and *P. aeruginosa* are pathogens frequently cultured in patients with COPD.[@b28-copd-11-2741] Especially, *H. influenzae* is observed in both stable state and during exacerbations.[@b29-copd-11-2741] *P. aeruginosa* is more often found in patients with most severely impaired lung function.[@b30-copd-11-2741] The effect of a specific etiology on the outcomes cannot be studied as the subgroups would become too small.

Strengths and limitations
-------------------------

The current study was based on a rather homogenous population of clinically stable patients with mild-to-severe COPD referred for PR. Therefore, differences in health status between subgroups are not expected to be associated with COPD-specific characteristics. Subgroups had comparable baseline characteristics concerning their level of airflow obstruction, smoking status, and hospital admissions.

Until now, most analyses[@b3-copd-11-2741],[@b4-copd-11-2741],[@b6-copd-11-2741] were based on patients who reported CB. However, it is difficult to assess this phenotype objectively as this definition relies on patients' perception of the symptoms and might be subject to recall bias. Studies that used sputum samples are few in number and are mainly focused on inflammatory parameters.[@b26-copd-11-2741] Moreover, no study differentiated patients with sputum samples based on their microbiological culture result. This is, to the best of our knowledge, the first study investigating differences between subgroups of patients with and without sputum production and with and without positive culture. Therefore, the current study increased the understanding of this specific subgroup of patients.

However, some aspects need to be taken into consideration regarding the current study. Although characterized as a patient with CB, more than half of them could not produce sputum during their 3 days' pre-rehabilitation assessment. No sputum induction was performed as part of the current study, so only patients with a spontaneous sample were included in the producer groups. Besides, SC+ were often classified as GOLD D and were frequent exacerbators, which could act as bias. However, it is known that patients with frequent exacerbations are more often colonized, which explains the present outcomes.[@b14-copd-11-2741] Moreover, no high-resolution computed tomography was performed to identify bronchiectasis, which is associated with increased sputum production.[@b31-copd-11-2741]

Conclusion
==========

In conclusion, health status is worse in patients with COPD who spontaneously produce sputum, especially when having a positive culture. Exercise capacity does not seem to be affected by sputum production. Further research is necessary to investigate the influence of sputum production and microbiology in the long term, especially when looking at positive cultures in relation to disease progression and outcomes of PR. Insight into the clinical profile of this subgroup of patients may contribute to specific recommendations, as not sputum per se seems to influence clinical outcomes, but having a positive culture.
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![Health status of NP vs SC− vs SC+ by CAT total score (**A**), CAT cough and phlegm (**B**), SGRQ-C total score (**C**), SGRQ-C domain scores (**D**), CCQ total score (**E**), and HADS score (**F**).\
**Notes:** Data are presented as mean ± SD. One-way ANOVA and post hoc Bonferroni test. \**P*\<0.05 compared to NP.\
**Abbreviations:** CAT, COPD Assessment Test; SGRQ-C, St George's Respiratory Questionnaire; CCQ, Clinical COPD Questionnaire; HADS, Hospital Anxiety and Depression scale; SC−, sputum producers with a negative culture; SC+, sputum producers with a positive culture; SD, standard deviation; ANOVA, analysis of variance; NP, nonsputum producers.](copd-11-2741Fig1){#f1-copd-11-2741}
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###### 

Baseline characteristics of NP vs SC− vs SC+

  Features                                                                NP (n=354)          SC− (n=111)                                             SC+ (n=53)                                              *P*-value
  ----------------------------------------------------------------------- ------------------- ------------------------------------------------------- ------------------------------------------------------- -----------
  Age (years)                                                             63.8±9.1            64.3±9.2                                                65.5±8.9                                                0.466
  Male sex                                                                184 (52.0)          68 (61.3)                                               36 (67.9)[a](#tfn2-copd-11-2741){ref-type="table-fn"}   0.037
  BMI (kg/m^2^)                                                           26.1±5.8            26.2±5.4                                                27.0±6.4                                                0.622
  COPD GOLD                                                                                                                                                                                                   \<0.001
   A                                                                      13 (3.7)            4 (3.6)                                                 2 (3.8)                                                 
   B                                                                      162 (45.8)          36 (32.4)                                               8 (15.1)                                                
   C                                                                      7 (2.0)             3 (2.7)                                                                                                         
   D                                                                      172 (48.6)          68 (61.3)                                               43 (81.1)[a](#tfn2-copd-11-2741){ref-type="table-fn"}   
  Current smoker                                                          72 (20.4)           32 (28.8)                                               10 (18.9)                                               0.362
  Pack-years[b](#tfn3-copd-11-2741){ref-type="table-fn"}                  40.0 (30.0--50.0)   40.0 (25.0--50.0)                                       41.0 (31.0--51.0)                                       0.350
  FEV~1~ (% predicted)                                                    49.0±20.0           48.7±19.2                                               45.6±21.4                                               0.525
  FEV~1~/FVC (Tiffeneau)                                                  37.9±12.1           36.8±11.8                                               36.5±13.8                                               0.579
  RV (% predicted)                                                        163.0±51.6          155.1±46.3                                              160.7±53.6                                              0.372
  TLC (% predicted)                                                       117.9±17.1          116.2±17.5                                              113.7±20.0                                              0.226
  DLCO (% predicted)                                                      49.5±17.5           50.2±16.9                                               46.2±15.8                                               0.391
  LTOT                                                                    82 (23.2)           24 (21.6)                                               19 (35.8)                                               0.103
  PaCO~2~ (kPa)[b](#tfn3-copd-11-2741){ref-type="table-fn"}               5.2 (4.7--5.6)      5.1 (4.7--5.6)                                          5.3 (4.9--5.9)                                          0.340
  PaO~2~ (kPa)[b](#tfn3-copd-11-2741){ref-type="table-fn"}                9.6 (8.7--10.4)     9.3 (8.3--10.3)                                         9.4 (8.4--10.4)                                         0.397
  Exacerbations (\<1 year)                                                                                                                                                                                    \<0.001
   0                                                                      101 (28.5)          23 (20.7)                                               4 (7.5)                                                 
   1                                                                      74 (20.9)           17 (15.3)                                               6 (11.3)                                                
   ≥2                                                                     179 (50.6)          71 (64.0)[a](#tfn2-copd-11-2741){ref-type="table-fn"}   43 (81.1)[a](#tfn2-copd-11-2741){ref-type="table-fn"}   
  Hospitalizations (\<1 year)                                                                                                                                                                                 0.061
   0                                                                      204 (57.6)          57 (51.4)                                               23 (43.4)                                               
   1                                                                      87 (24.6)           23 (20.7)                                               14 (26.4)                                               
   ≥2                                                                     63 (17.8)           31 (27.9)                                               16 (30.2)                                               
  ICU admissions (\<1 year)[c](#tfn4-copd-11-2741){ref-type="table-fn"}                                                                                                                                       0.597
   0                                                                      312 (92.9)          100 (95.2)                                              51 (98.1)                                               
   1                                                                      21 (6.3)            4 (3.8)                                                 1 (1.9)                                                 
   ≥2                                                                     3 (0.9)             1 (1.0)                                                 --                                                      
  Symptoms of CB                                                          89 (26.1)           46 (45.5)[a](#tfn2-copd-11-2741){ref-type="table-fn"}   32 (61.5)[a](#tfn2-copd-11-2741){ref-type="table-fn"}   \<0.001
  mMRC[d](#tfn5-copd-11-2741){ref-type="table-fn"}                                                                                                                                                            0.825
   0                                                                      7 (2.0)             3 (2.8)                                                                                                         
   1                                                                      62 (17.7)           16 (14.7)                                               7 (13.5)                                                
   2                                                                      134 (38.2)          42 (38.5)                                               17 (32.7)                                               
   3                                                                      82 (23.4)           28 (25.7)                                               17 (32.7)                                               
   4                                                                      66 (18.8)           20 (18.3)                                               11 (21.2)                                               

**Notes:** Data are presented as mean ± SD, median (interquartile range), or n (%).

*P*\<0.05 compared to NP;

not normally distributed;

missing NP: n=18; SC−: n=6; SC+: n=1;

missing NP: n=3; SC−: n=2; SC+: n=1.

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; FEV~1~, forced expiratory volume in 1 second; FVC, forced Vital capacity; RV, residual volume; TLC, total lung capacity; DLCO, diffusing capacity for carbon monoxide; LTOT, long-term oxygen therapy; CB, chronic bronchitis; mMRC, modified Medical Research Council; ICU, intensive care unit; SD, standard deviation; NP, nonsputum producers; SC+, sputum producers with a positive culture; SC−, sputum producers with a negative culture.

###### 

Inflammatory parameters, by peripheral blood collection, of NP vs SP

  Features                                                                                                                 NP (n=354)       SP (n=164)       *P*-value
  ------------------------------------------------------------------------------------------------------------------------ ---------------- ---------------- -----------
  CRP (mg/L)[a](#tfn8-copd-11-2741){ref-type="table-fn"}                                                                   2.6 (0.9--7.0)   3.3 (1.1--8.0)   0.158
  Erythrocytes (10^E12^/L)                                                                                                 4.7±0.4          4.7±0.5          0.490
  Leukocytes (10^E9^/L)                                                                                                    8.0±2.3          8.3±2.5          0.153
  Granulocytes (%)                                                                                                         60.7±9.6         59.5±10.3        0.198
  Lymphocytes (%)                                                                                                          28.2±8.1         28.7±8.7         0.538
  Monocytes (%)                                                                                                            8.6±3.0          9.0±3.0          0.119
  Eosinophilic granulocytes (%)[a](#tfn8-copd-11-2741){ref-type="table-fn"},[b](#tfn9-copd-11-2741){ref-type="table-fn"}   3.0 (2.0--4.0)   3.0 (2.0--5.0)   0.205
   ≤2%                                                                                                                     86 (45.5)        35 (39.3)        0.332
   \>2%                                                                                                                    103 (54.5)       54 (60.7)        0.205

**Notes:** Data are presented as mean ± SD, median (interquartile range), or n (%).

Not normally distributed;

n=278.

**Abbreviations:** CRP, C-reactive protein; NP, nonsputum producers; SP, sputum producers; SD, standard deviation.
